Mechanistic insights into the role of α1-adrenergic receptors in lower urinary tract symptoms

被引：9

作者：

Michelotti G.A. ^{[1
]}

Schwinn D.A. ^{[1
]}

机构：

[1] Department of Anesthesiology, Duke University Medical Center, Box 3094, Durham, 27710, NC

来源：

Current Urology Reports | 2004年 / 5卷 / 4期

关键词：

Benign Prostatic Hyperplasia; Bladder Outlet Obstruction; Finasteride; Irritative Symptom; Lower Urinary Tract Symptom;

D O I：

10.1007/s11934-004-0048-0

中图分类号：

学科分类号：

摘要：

Although α1AR antagonists have been used for more than two decades to treat lower urinary tract symptoms (LUTS), we have little understanding of the mechanistic basis of their efficacy and their role in the development of LUTS. It is clear that α1ARs play a critical role in bladder dysfunction and recent data suggest that α1AR subtype switching may play a key role in this pathophysiology, providing support for use of α1dAR-selective antagonists in treating irritative symptoms. This review seeks to summarize current levels of understanding in this field and discusses new concepts that suggest increased levels of complexity involving cross-talk in multiple receptor systems. Effective therapeutic modalities likely will involve increased subtype selective α1AR antagonists and other pharmacodynamic factors. © 2004, Current Science Inc.

引用

页码：258 / 266

页数：8

共 78 条

[1]

Boyle P., Robertson C., Mazzetta C., Et al., The prevalence of lower urinary tract symptoms in men and women in four centres: the UrEpik study, BJU Int, 92, pp. 409-414, (2003)

[2]

Committee APG A.P.G., Benign prostatic hyperplasia: guideline on the management of benign prostatic hyperplasia, J Urol, 170, pp. 530-547, (2003)

[3]

Rees R.W., Foxwell N.A., Ralph D.J., Et al., Y-27632, a Rho-kinase inhibitor, inhibits proliferation and adrenergic contraction of prostatic smooth muscle cells, J Urol, 170, pp. 2517-2522, (2003)

[4]

Schwinn D.A., Michelotti G.A., Alpha1-adrenergic receptors in the lower urinary tract and vascular bed: potential role for the alpha1d subtype in filling symptoms and effects of ageing on vascular expression, BJU Int, 85, pp. 6-11, (2000)

[5]

MacDonald D., McNicholas T.A., Drug treatments for lower urinary tract symptoms secondary to bladder outflow obstruction: focus on quality of life, Drugs, 63, pp. 1947-1962, (2003)

[6]

Andersson K.E., Storage and voiding symptoms: pathophysiologic aspects, Urology, 62, pp. 3-10, (2003)

[7]

Roehrborn C.G., McConnell J.D., Saltzman B., Et al., Storage (irritative) and voiding (obstructive) symptoms as predictors of benign prostatic hyperplasia progression and related outcomes, Eur Urol, 42, pp. 1-6, (2002)

[8]

Blue D., Zinner N., Grino P., Et al., Ro700004, a selective a1phaadrenoceptor antagonist, does not improve lower urinary tract symptoms in men with benign prostatic hyperplasia, J Urol, 167, (2002)

[9]

Nickel J.C., The use of alpha1-adrenoceptor antagonists in lower urinary tract symptoms: beyond benign prostatic hyperplasia, Urology, 62, pp. 34-41, (2003)

[10]

Djavan B., Shariat S., Fakhari M., Et al., Neoadjuvant and adjuvant alpha-blockade improves early results of high-energy transurethral microwave thermotherapy for lower urinary tract symptoms of benign prostatic hyperplasia: a randomized, prospective clinical trial, Urology, 53, pp. 251-259, (1999)

← 1 2 3 4 5 6 7 8 →